동물용 구충제 시장 : 제품 유형, 대상 동물, 기생충 유형, 투여 경로, 유통 채널, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Animal Parasiticides Market is projected to grow by USD 29.78 billion at a CAGR of 10.06% by 2032.

Animal parasiticides are essential veterinary pharmaceuticals used to prevent, treat, and control ectoparasites and endoparasites in companion animals and food-producing livestock. The market spans flea, tick, mite, lice, heartworm, gastrointestinal worm, and broad-spectrum endectocide solutions delivered through oral, topical, injectable, pour-on, spray, collar, and feed-additive formats.

Demand is supported by rising pet ownership, premiumization of companion animal care, livestock productivity requirements, and increasing awareness of zoonotic disease risks. Regulatory oversight from agencies such as the U.S. FDA Center for Veterinary Medicine, the European Medicines Agency, and national veterinary authorities continues to shape product claims, safety requirements, residue limits, withdrawal periods, and environmental stewardship expectations.

For manufacturers, distributors, veterinarians, livestock producers, and animal health investors, sustainable growth depends on balancing efficacy, convenience, resistance management, affordability, and compliance with evolving rules on residues, antiparasitic stewardship, pharmacovigilance, and environmental exposure.

Transformative Shifts Reshaping Animal Parasiticides

The animal parasiticides landscape is shifting from reactive parasite treatment toward year-round prevention, risk-based dosing, and integrated parasite management. Companion animal owners increasingly favor convenient monthly or longer-duration products, while livestock producers prioritize herd-level protocols that protect productivity, animal welfare, and food safety.

Product portfolios are also evolving. Broad-spectrum combinations, palatable oral formulations, long-acting injectables, pour-on treatments, collars, and species-specific delivery systems are gaining strategic importance as veterinarians and producers seek dependable compliance. At the same time, documented parasite resistance to established drug classes is driving demand for diagnostic surveillance, rotation strategies, refugia-based approaches, and new modes of action.

Digital commerce, veterinary telehealth, and direct-to-consumer education are changing how pet owners discover and purchase parasite prevention products. However, prescription controls, counterfeit-product risk, label-compliance requirements, and the need for veterinary guidance keep professional channels central to responsible parasiticide use.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across animal parasiticide research, commercialization, and stewardship. In discovery and formulation, AI-enabled molecular screening, predictive toxicology, and pharmacokinetic modeling can help prioritize candidates, refine dose-form development, and identify potential safety concerns before costly field studies.

In the field, AI can strengthen parasite surveillance by combining veterinary clinic records, diagnostic results, climate data, geospatial signals, livestock movement patterns, and farm-management information to anticipate seasonal parasite pressure. This supports targeted treatment recommendations and helps reduce unnecessary exposure that may accelerate resistance.

AI also improves commercial execution through demand-planning analytics, pharmacovigilance signal detection, supply-chain risk monitoring, and personalized customer education. The greatest value will come from governed systems that protect data privacy, preserve veterinarian oversight, document model limitations, and align algorithmic recommendations with approved product labels and local regulations.

Key Regional Insights

Asia-Pacific is a high-priority region due to its large livestock base, expanding aquaculture and poultry sectors, and rising companion animal adoption in urban markets. China, India, Japan, South Korea, Australia, and ASEAN countries show different demand patterns, ranging from cost-effective livestock dewormers and ectoparasiticides to premium flea, tick, and heartworm prevention products for pets. Tropical and subtropical climates across parts of the region support persistent parasite pressure, while developed markets such as Japan, South Korea, and Australia place greater emphasis on safety, compliance, and veterinary-led preventive care.

North America remains one of the most mature regions, supported by high veterinary service utilization, advanced companion animal care, broad retail and clinic channels, and established regulatory oversight. The United States and Canada emphasize year-round parasite prevention for dogs and cats, including heartworm, flea, and tick control, while food-animal demand is influenced by productivity, residue compliance, withdrawal-period adherence, and veterinary supervision. Latin America is shaped by large cattle and companion animal populations, with Brazil and Mexico playing central roles in demand for tick control, gastrointestinal worm management, ectoparasiticides, endoparasiticides, and endectocides.

Europe is driven by stringent regulatory standards, pharmacovigilance, residue monitoring, and sustainability expectations, particularly within the European Union, where veterinary medicinal product rules and environmental risk assessment shape market access. The Middle East is supported by premium companion animal care, equine and camel health requirements, and livestock health programs in GCC markets. Africa presents long-term opportunity tied to livestock disease control, food security, smallholder productivity, and access to affordable, quality-assured veterinary medicines, with parasite control remaining important across cattle, sheep, goats, poultry, and companion animals.

Key Group Insights

ASEAN markets are gaining relevance as livestock intensification, pet ownership, and veterinary retail networks expand across Southeast Asia. The region's tropical climate sustains year-round parasite pressure, making effective flea, tick, mite, and helminth control important for companion animals and production animals. Variability in veterinary access and purchasing power also increases the importance of affordable formulations, distributor quality, and user education.

The GCC is characterized by high-income urban pet care, equine and camel health requirements, and growing interest in premium veterinary services, with demand shaped by climate-related parasite exposure, import dependence, and high expectations for product authenticity. In the European Union, harmonized veterinary medicinal product rules, environmental risk assessment, residue controls, and pharmacovigilance make regulatory compliance a core competitive factor for parasiticide suppliers.

BRICS countries represent large-volume relevance because of major livestock populations, fast-growing pet care markets, and increasing domestic animal health manufacturing capacity. G7 markets are typically innovation-led, with strong demand for branded companion animal parasiticides, advanced veterinary diagnostics, and label-driven preventive care. NATO member economies overlap significantly with established regulatory systems and high standards for supply security, pharmacovigilance, veterinary infrastructure, and resilience of essential animal health products.

Key Country Insights

The United States is a global reference market for companion animal parasiticides, driven by veterinary recommendation, heartworm prevention, flea and tick control, retail availability, and high pet healthcare engagement. Canada shows similar preventive-care behavior, with seasonal and regional parasite risk influencing product selection, while Mexico combines expanding companion animal care with livestock parasite control needs. Brazil is a major demand center for cattle parasiticides, tick control, endectocides, and a growing pet care segment, supported by its large livestock base and strong veterinary distribution networks.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are supported by developed veterinary networks, premium pet ownership, and strict product safety standards. Germany and France emphasize regulated veterinary medicine use and quality assurance, while Italy and Spain combine companion animal demand with livestock parasite management needs in diverse production systems. Russia remains relevant due to livestock scale and companion animal demand, although trade, regulatory, and supply-chain conditions influence market access and product availability.

China and India offer significant long-term potential because of large animal populations, rising protein demand, expanding pet ownership, and growing attention to animal disease prevention. China's companion animal sector is increasingly urban and premium-oriented, while India's demand is supported by dairy, small ruminants, poultry, and companion animal healthcare. Japan and South Korea are premium companion animal markets with strong expectations for safety, convenience, and veterinary guidance. Australia's livestock and companion animal sectors require robust parasite management due to diverse climate zones, biosecurity priorities, tick and helminth pressure, and well-established veterinary practices.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated parasiticide products that combine proven efficacy with convenience, safety, and adherence benefits. Investments in long-acting formulations, broad-spectrum combinations, palatable delivery, precision dosing, and species-specific administration can improve customer retention and veterinarian confidence.

Companies should strengthen resistance-management programs by supporting diagnostic testing, parasite surveillance, rotation guidance, refugia-based education, and responsible-use training. Clear stewardship messaging is increasingly important as regulators, veterinarians, producers, and pet owners scrutinize environmental exposure, residue compliance, and unnecessary dosing.

Commercial teams should align channel strategy with local regulations and customer behavior. In mature markets, veterinary endorsement, digital education, subscription models, label-compliant communication, and pharmacovigilance excellence are critical. In emerging markets, affordability, cold-chain resilience where relevant, distributor quality, anti-counterfeit measures, and training for veterinary professionals can unlock sustainable growth.

Research Methodology

This executive summary is built from a structured research approach combining secondary research, evidence triangulation, and expert interpretation. Sources typically reviewed for animal parasiticide analysis include veterinary regulatory agencies, product labels, pharmacovigilance guidance, animal health associations, peer-reviewed parasitology literature, livestock and pet population indicators, disease surveillance publications, and trade data where available.

The methodology evaluates the market by animal type, parasite type, product class, route of administration, distribution channel, regulatory environment, and geography. Demand signals are cross-checked against regulatory approvals, disease prevalence patterns, veterinary practice trends, livestock production systems, companion animal spending behavior, climate-linked parasite risk, and public animal health priorities.

Insights are validated through consistency checks across public datasets, clinical and field-use evidence, regional policy developments, and documented veterinary practice patterns. AI-assisted synthesis may support pattern recognition and terminology standardization, but final interpretation requires human review to ensure accuracy, relevance, and compliance with verified market evidence.

Conclusion

The animal parasiticides market is positioned for continued strategic importance as pet owners, veterinarians, livestock producers, and public health stakeholders intensify focus on parasite prevention, animal welfare, food security, and zoonotic disease risk reduction. Momentum will be strongest for organizations that deliver reliable efficacy, convenient administration, responsible stewardship, and region-specific access strategies.

Artificial intelligence, improved diagnostics, climate-informed surveillance, and targeted treatment models will help reshape competition, but regulatory compliance and veterinarian trust will remain decisive. Organizations that pair innovation with education, pharmacovigilance, quality assurance, and sustainability will be best placed to create long-term value in the global animal parasiticides industry.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Animal Parasiticides Market, by Product Type

• 7.1. Ectoparasiticides
  • 7.1.1. Insecticides
  • 7.1.2. Acaricides
  • 7.1.3. Larvicides
• 7.2. Endoparasiticides
  • 7.2.1. Anthelmintics
  • 7.2.2. Antiprotozoals
• 7.3. Endectocides
  • 7.3.1. Avermectins
  • 7.3.2. Milbemycins

8. Animal Parasiticides Market, by Animal Type

• 8.1. Companion Animal
  • 8.1.1. Dogs
  • 8.1.2. Cats
  • 8.1.3. Horses
• 8.2. Livestock
  • 8.2.1. Cattle
  • 8.2.2. Poultry
  • 8.2.3. Swine
  • 8.2.4. Sheep
• 8.3. Aquaculture Animals

9. Animal Parasiticides Market, by Parasite Type

• 9.1. External Parasite
• 9.2. Internal Parasite

10. Animal Parasiticides Market, by Route Of Administration

• 10.1. Injectable
• 10.2. Oral
• 10.3. Topical

11. Animal Parasiticides Market, by Distribution Channel

• 11.1. Online Pharmacies
• 11.2. Pharmacies And Drug Stores
• 11.3. Veterinary Hospitals And Clinics

12. Animal Parasiticides Market, by End User

• 12.1. Veterinary Institutions
• 12.2. Livestock Farms
• 12.3. Pet Owners
• 12.4. Animal Breeding Centers
• 12.5. Research Laboratories

13. Animal Parasiticides Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Animal Parasiticides Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Animal Parasiticides Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Animalcare Group plc
• 17.2. Bayer AG
• 17.3. Bimeda Animal Health Ltd
• 17.4. Boehringer Ingelheim International GmbH
• 17.5. Ceva Sante Animale
• 17.6. Chanelle Pharma
• 17.7. Dechra Pharmaceuticals PLC
• 17.8. ECO Animal Health Group plc
• 17.9. Elanco Animal Health Incorporated
• 17.10. Heska Corporation
• 17.11. Hester Biosciences Limited
• 17.12. Huvepharma EOOD
• 17.13. Indian Immunologicals Limited
• 17.14. Intas Pharmaceuticals Ltd
• 17.15. KRKA d.d.
• 17.16. Kyoritsu Seiyaku Corporation
• 17.17. Merck & Co Inc
• 17.18. Neogen Corporation
• 17.19. Norbrook Laboratories Ltd
• 17.20. Ourofino Saude Animal
• 17.21. PetIQ Inc
• 17.22. Phibro Animal Health Corporation
• 17.23. VETANCO S.A.
• 17.24. Vetoquinol SA
• 17.25. Virbac SA
• 17.26. Zoetis Inc